Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02304835
Other study ID # BETINA
Secondary ID
Status Completed
Phase N/A
First received November 25, 2014
Last updated December 4, 2014
Start date May 2013
Est. completion date November 2013

Study information

Verified date December 2014
Source Nordic Pharma SAS
Contact n/a
Is FDA regulated No
Health authority France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santéFrance: French Data Protection AuthorityFrance: Conseil National de l'Ordre des Médecins
Study type Observational

Clinical Trial Summary

This study was a national, longitudinal, prospective, observational survey, carried out in metropolitan France, with a sampling of 21 birth control centres.

The aim of this study was to assess, in real life conditions, the benefit of a urinary semi-quantitative test (hCG Duo 5-1000) in the follow-up of medical abortion by analysing the concordance between qualitative results from the urinary test and quantitative values from the beta-hCG blood measurement.


Recruitment information / eligibility

Status Completed
Enrollment 322
Est. completion date November 2013
Est. primary completion date November 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult women (18 years old or more), pregnant the day of the medical examination and asking for medical abortion.

- Patients agreeing to participate in the study after have been informed orally by the physician and given the information sheet.

- Informed patients accepting the computer processing of their medical data and their right of access and correction.

Exclusion Criteria:

- Patients with more than 49 Days of Amenorrhea (DA) for private practice and 63 DA for hospital practice.

- Patients with contraindications to medical abortion.

- Patients with severe and progressive disease.

- Patients unable to complete a questionnaire.

- Patients refusing to participate in the study.

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
France Cabinet Médical Paris

Sponsors (1)

Lead Sponsor Collaborator
Nordic Pharma SAS

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary concordance between qualitative results from the urinary test and quantitative values from the beta-hCG blood measurement. There was concordance if :
The result of urinary test is < 1000 IU/L and the value of ß-hCG blood measurement was < 1000 IU/L, Or if
The result of urinary test is = 1000 iu/L and the value of ß-hCG blood measurement was = 1000 IU/L.
There was discrepancy if:
The result of urinary test is = 1000 IU/L and the value of ß-hCG blood measurement was < 1000 IU/L, Or if
The result of urinary test is < 1000 IU/L and the value of ß-hCG blood measurement was = 1000 IU/L.
At the follow-up at 2-3 weeks after inclusion No
Secondary Acceptability of the urinary semi-quantitative test by the patient The analysis of the acceptability is descriptive:
The rate of patients who performed the urinary test.
Assessment of the urinary test by physicIan : very easy/easy/difficult/Impossible
The assessment by the patient: questionnaire (Have you found the explanations given sufficient for performing the test?, How did you find the carrying out of this test? What are your feelings about checking the results of the medical abortion yourself?)
at the follow up at 2-3 weeks after the inclusion No